Lila retains stakes in discoveries

The real upside is that Lila can turn a services business into an asset ownership business. A customer project pays once for discovery work. A retained stake in an antibody, catalyst, or material can pay again through milestone payments, royalties, licensing fees, or equity in a spinout. That matters because Lila already controls the full loop from model generation to robotic testing, which gives it a natural way to decide which outputs are valuable enough to keep developing.

• Lila is built to create proprietary outputs, not just run experiments faster. Its autonomous labs have already been used to generate and validate novel antibodies, peptides, binders, and non platinum group metal catalysts, which are the kind of discrete assets that can be licensed or developed into standalone companies.
  1 sacra 2 flagshippioneering
• This is a very different revenue profile from infrastructure players like Benchling. Benchling sells software that helps scientists design, document, and track experiments across 1,200 customers, while Lila can potentially own pieces of the scientific products that come out of its system, which creates a path to much larger but slower monetization.
  3 sacra 4 sacra
• There is precedent for platform companies in adjacent scientific markets turning a core technology into product layers and new business lines. Apeel started with a shelf life coating, then used its position inside customer operations to add adjacent capabilities, showing how a discovery platform can expand from doing work for customers into owning more of the value chain.
  5 sacra

The next step is likely a split model where Lila sells discovery capacity to fund operations, while selectively keeping rights to the highest potential programs. If that works, the company starts to look less like a contract research shop and more like a repeat creator of licensable therapeutics, materials, and spinouts across multiple scientific domains.